ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1986

Adalimumab:TNF Complexes Are Cleared More Efficiently By Human Osteoclasts Than Those with Etanercept through Fcg-Receptor Binding and Internalization

Bohdan P. Harvey, Joel Cohen-Solal and Zehra Kaymakcalan, Biologics, AbbVie Bioresearch Center, Worcester, MA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Adalimumab, etanercept, Fc receptors, osteoclasts and tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Title: Osteoarthritis and Joint Biology – Basic Science Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: TNF-alpha (TNFa) has been shown to contribute to osteoclastogenesis (OCgenesis) independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast (OC) development. We have previously demonstrated that TNF enhances the kinetics of RANKL-induced human OCgenesis and that its effects are mitigated more effectively by the anti-TNF biologic adalimumab (ADA) as compared to etanercept (ETN). The objective of this study was to determine whether Fc-gamma receptor (FcgR)-mediated internalization of the biologic:TNF complexes is a contributing mechanism responsible for the difference in effectiveness between ADA and ETN in preventing TNF-enhanced OCgenesis.

Methods: TNF biologics [ADA and ETN] alone or in preformed complexes with TNFa at 50:1 molar ratio were tested for FcgR binding by flow cytometry using CHO stably transfected with human FCGRs (FcgRI, FcgRIIA, -RIIB, -RIIC, FcgRIIIA & -RIIIB). FcgR expression and binding of preformed biologic:TNF complexes at 10:1 ratio +/- FcgR blocking antibodies to primary human OC precursors (OCP) was evaluated by flow cytometry. FcgR-mediated internalization was assessed by monitoring a reduction in OC survival in response to preformed biologic:TNF complexes (25:1 ratio) bound with saporin (ZAP), a ribosome-inactivating toxin, as anti-human Fc IgG Fab conjugate +/- FcgR blocking antibodies.

Results: The binding study to CHO (human FcgRs) cell lines showed that monomeric ADA and ETN bind similarly to FcgR (highly on high affinity FcgR and loosely on low affinity FcgRs) while preformed biologics: TNF complexes bind differently. ADA:TNF complexes bind to low affinity FcgR, whereas ETN:TNF keep a monomeric binding profile with no gain of binding to low affinity FcgR. OCP were found to express mostly FcgRII early in development with predominant binding of only ADA:TNF, not ETN:TNF, to this FcgR with additional binding to undefined receptor(s). Despite subsequent increases in FcgRI and RIII later on, ADA:TNF still preferentially bound to FcgRII on the matured OCP with minimal binding to RIII, whereas ETN:TNF binding was observed only to FcgRI. Exposure of OCP to ADA:TNF:ZAP(toxin) complexes led to a significant reduction (4-fold) in mature OC due to complex internalization as compared to human IgG:ZAP+TNF conditions that was partially rescued only with the addition of FcgRII blocking antibody. Interestingly, a 1.5-fold reduction in mature OC was observed with ETN:TNF:ZAP.

Conclusion: Our in vitro findings demonstrate that human OCP can bind and internalize ADA:TNF complexes more efficiently than ETN:TNF complexes. In addition, this process is partially mediated through FcgRII. Clearance of the ADA:TNF complexes may help reduce exposure of the OCP to localized TNF by removing TNF more effectively in the joint environment. Additional in vivo analysis need to be done to verify these in vitro findings.


Disclosure: B. P. Harvey, AbbVie Inc., 3,AbbVie Inc., 1; J. Cohen-Solal, AbbVie Inc., 3,AbbVie Inc., 1; Z. Kaymakcalan, AbbVie Inc., 3,AbbVie Inc., 1.

To cite this abstract in AMA style:

Harvey BP, Cohen-Solal J, Kaymakcalan Z. Adalimumab:TNF Complexes Are Cleared More Efficiently By Human Osteoclasts Than Those with Etanercept through Fcg-Receptor Binding and Internalization [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/adalimumabtnf-complexes-are-cleared-more-efficiently-by-human-osteoclasts-than-those-with-etanercept-through-fcg-receptor-binding-and-internalization/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adalimumabtnf-complexes-are-cleared-more-efficiently-by-human-osteoclasts-than-those-with-etanercept-through-fcg-receptor-binding-and-internalization/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology